Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
A kidney hierarchical composite endpoint (HCE) combining kidney clinical events, and estimated glomerular filtration rate (eGFR) slope has been developed and validated. The kidney HCE prioritizes the most clinically relevant kidney event for each participant and offers a more efficient and clinically meaningful approach to assessing treatment effects than a traditional composite outcome. However, its usefulness has not been studied in Japanese populations.
Methods for DAPA-CKD and the kidney HCE have been previously described. The kidney HCE comprises the following components in hierarchical order: 1) death, 2) kidney failure with replacement therapy (KFRT; dialysis or transplantation), 3) sustained eGFR <15 mL/min/1.73m2, 4) sustained 57% eGFR decline from baseline, 5) sustained 50% eGFR decline from baseline, 6) sustained 40% eGFR decline from baseline, and 7) patient-level eGFR slope. Each dapagliflozin participant was compared with each placebo participant. Participants who did not experience any of components 1-6 were compared according to their eGFR slope. A “win”, “loss”, or “tie” for dapagliflozin was determined for each comparison, and win odds were calculated according to the following formula: (wins + ties ×0.5) / (losses + ties ×0.5). Win odds >1.0 were considered indicative of a clinical benefit.
In the DAPA-CKD trial, the Japanese subgroup consisted of 244 participants; 24.2% were female. At baseline, mean age was 65.6 years, mean eGFR was 40.4 mL/min/1.73m2, and median urine-albumin-to-creatinine ratio was 927.8 mg/g. The win odds (95% confidence interval) for dapagliflozin were 1.74 (1.29, 2.35), with corresponding nominal p-value of <0.001 (Figure 1).
The results of the kidney HCE analysis in Japanese participants in the DAPA-CKD trial were consistent with the main results, showing increased odds of favorable kidney outcomes when treated with dapagliflozin compared to placebo. These findings confirm the efficacy of dapagliflozin in Japanese patients with CKD, and support the use of the kidney HCE in CKD trials that include Japanese participants.
